ArticleBiochemistry and biophysics reports2026
Molecular crosstalk between AHR, CYP1B1, and ITGAM in diabetic nephropathy: Integrated insights from bioinformatics and experimental validation.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation and a progressive loss of kidney function are hallmarks of diabetic nephropathy (DN). Th22 cells are mainly regulated by the transcription factor AHR, which is essential for their differentiation and inflammatory responses. This study aims to investigate the regulatory role of Th22 cells in the progression of DN. The GEO database was used to retrieve the GSE142025 (DN) and GSE135390 (Th22) datasets, which provided transcriptomic profiles for gene expression analysis. WGCNA was employed to identify gene co-expression modules strongly correlated with DN progression. Gene expression levels were validated by real-time PCR in 90 PBMC samples (30 per group: T2DM, DN, and healthy controls). Gene-drug interactions were subsequently predicted using the DGIdb database. In DN, 4006 differentially expressed genes (DEGs) were identified, while 831 DEGs were detected in Th22 cells. After intersecting these DEGs using a Venn diagram tool, 106 common genes were found. Following the construction of a protein-protein interaction network using the STRING database and subsequent analysis in Cytoscape, ITGAM was identified as the central hub gene. Real-time PCR analysis demonstrated significantly elevated expression levels of AHR (a major transcription factor of Th22 cells), ITGAM, and CYP1B1 (a downstream target gene of AHR) in DN patients compared to those with T2DM and healthy controls. Changes in the transcript levels of ITGAM, CYP1B1, and AHR were associated with renal biochemical parameters. Additionally, 60 drugs were predicted to regulate AHR, 12 targeted ITGAM, and 33 targeted CYP1B1. This study highlights the potential role of AHR, ITGAM, and CYP1B1 in the pathogenesis of DN. Their altered expression patterns suggest they could serve as useful biomarkers for monitoring disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.